Glenmark Life Sciences is the leading manufacturer of Active Pharmaceutical Ingredients (APIs). The company develops, manufactures, and supplies high-quality APIs for Cardiovascular disease (CVS), central nervous system disease (CNS), pain management, and diabetes, gastrointestinal disorders, anti-infective, and other therapeutic areas.
It further operates in Contract Development and manufacturing operations (CDMO) to offer services to specialty Pharmaceutical companies.
Company’s product portfolio comprises of 120 APIs across various therapeutic segments
Currently, it has 4 manufacturing facilities at Ankleshwar and Dahej in Gujarat and Mohol and Kurkumbh in Maharashtra State with an aggregate annual installed capacity of
725.8 KL as of December 31, 2020.
IPO – Opening 27 July, 2021, Closing- 29 July, 2021.
Shares Allotment -03 August, 2021 IPO Listing on 29 July, 2021
Issue Price – Rs 695-720 Per Equity Shares Lot Size -20 Shares.
Minimum Investment – Rs 14,400 per Lot
